[{"orgOrder":0,"company":"Anima Medical Centre","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"D","amount":"$2,420.0 million","upfrontCash":"$120.0 million","newsHeadline":"Anima Biotech Announces Strategic Collaboration with Takeda to Discover and Develop mRNA Translation Modulators for Neurological Diseases","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"BELGIUM","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"March 2021","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Preclinical"},{"orgOrder":0,"company":"Anima Medical Centre","sponsor":"Moderna Therapeutics","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Anima Research Center Participating In A Trial For An Investigational RSV Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"BELGIUM","productType":"Vaccine","productStatus":"New Molecular Entity","date":"September 2022","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical"}]
Find Clinical Drug Pipeline Developments & Deals by Anima Medical Centre
Anima is collaborating with the U.S. pharmaceutical company Moderna, among others, to evaluate an RSV vaccine under development, aimed at persons over 60 years of age.
Under the terms of the agreement, Anima will use its Translation Control Therapeutics platform to discover novel mRNA translation modulators against the collaboration targets.